Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women

International Journal of Cancer

Volumn 125, Issue 4, 2009, Pages 837-843

  Sangrajrang, Suleeporn ^a   Sato, Yasunori ^b   Sakamoto, Hiromi ^b   Ohnami, Sumiko ^b   Laird, Nan M ^c   Khuhaprema, Thiravud ^a   Brennan, Paul ^d   Boffetta, Paolo ^d   Yoshida, Teruhiko ^b  

^a NATIONAL CANCER INSTITUTE   (Thailand)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Breast cancer; Estrogen metabolizing enzyme; Single nucleotide polymorphisms

Indexed keywords

AROMATASE; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; ESTROGEN;

ARTICLE; BREAST CANCER; CANCER RISK; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME METABOLISM; ESTROGEN METABOLISM; ESTROGEN SYNTHESIS; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A2; ENZYMES; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ARYL HYDROCARBON; RECEPTORS, ESTROGEN; RISK FACTORS; STEROID 17-ALPHA-HYDROXYLASE; THAILAND;

EID: 67650091388     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24434     Document Type: Article

References (36)

1. Althuis MD, Dozier JM, Anderson WF, Devesa SS, Brinton LA. Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005;34:405-12.
2. Hsieh CC, Trichopoulus D, Katsouyanni K, Yuasa S. Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: associations and interactions in an international case-control study. Int J Cancer 1990;46:796-800.
3. Stoll BA, Vatten LJ, Kvinnsland S. Does early physical maturity influence breast cancer risk? Acta Oncol 1994;33:171-6.
4. Nagata C, Kawakami N, Shimizu H. Trends in the incidence rate and risk factors for breast cancer in Japan. Breast Cancer Res Treat 1997;44:75-82.
5. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10.
6. Bernstein L, Yuan JM, Ross RK, Pike MC, Hanisch R, Lobo R, Stanczyk F, Gao YT, Henderson BE. Serum hormone levels in premenopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control 1990;1:51-8.
7. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-6.
8. Kristensen NV, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. CYP17 and breast cancer risk: the polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59:2825-8.
9. Ye Z, Parry JM. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002;17:119-26.
10. Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, Saxena S. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J Hum Genet 2007;52:159-65.
11. Nebert DW. Elevated estrogen 16α-hydroxylase activity: is this a genotoxic or nongenotoxic biomarker in human breast cancer risk? J Natl Cancer Inst 1993;85:1888-91.
12. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 1997;94:10937-42.
13. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci 1995;768:91-100.
14. van Aswegen CH, Purdy RH, Wittliff JL. Binding of 2-hydroxyestradiol and 4-hydroxyestradiol to estrogen receptors from human breast cancers. J Steroid Biochem 1989;32:485-92.
15. Kabat GC, Chang CJ, Sparano JA, Sepkovie DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997;6:505-9.
16. Bradlow L, Telang NT, Osborn MP. Estrogen metabolites as bioreactive modulators of tumor initiators and promoters. Adv Exp Med Biol 1996;387:285-96.
17. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27.
18. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 1996;93:3294-6.
19. Mitrunen K, Hivonen A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 2003;544:9-41.
20. Gooderham NJ, Murray S, Lynch AM, Edwards RJ, Yadollahi-Farsani M, Bratt C, Rich KJ, Zhao K, Murray BP, Bhadresa S, Crosbie SJ, Boobis AR, et al. Heterocyclic amines: evaluation of their role in diet associated human cancer. Br J Clin Pharmacol 1996;42:91-8.
21. Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9.
22. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T. Detection of three genetic polymorphisms in the 50-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 1999;90:899-902.
23. Lurie G, Maskarinec G, Kaaks R, Stanczyk FZ, Le Marchand L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:1521-7.
24. Le Marchand L, Donlon T, Kolonel LN, Henderson BE, Wilkens LR. Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005;14: 1998-2003.
25. Long JR, Egan KM, Dunning L, Shu XO, Cai Q, Cai H, Dai Q, Holtzman J, Gao YT, Zheng W. Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet Genomics 2006;16:237-43.
26. Rebbeck TR, Troxel AB, Walker AH, Panossian S, Gallagher S, Shatalova EG, Blanchard R, Norman S, Bunin G, DeMichele A, Berlin M, Schinnar R, et al. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev 2007;16:444-50.
27. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rundai P, Fabianova E, Mates D, Foretova L, Janout V, Benko V, Gaborieau V, et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007;28:1287-93.
28. Takata Y, Maskarinec G, Le Marchand L. Breast density and polymorphisms in genes coding for CYP1A2 and COMT: the Multiethnic Cohort. BMC Cancer 2007;7:30.
29. Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, Saleh TM. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 2006;3:551-8.
30. Sim SC, Risinger C, Dahl ML, Aklillu E, Chistensen M, Bertilsson L, Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-13.
31. Justenhoven C, Hamann U, Pierl CB, Baisch C, Harth V, Rabstein S, Spickenheuer A, Pesch B, Bruning T, Winter S, Ko YD, Brauch H. CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat, in press.
32. Wong JM, Harper PA, Meyer UA, Bock KW, Morike K, Lagueux J, Ayotte P, Tyndale RF, Sellers EM, Manchester DK, Okey AB. Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics 2001;11:85-94.
33. Horard B, Vanacker JM. Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J Mol Endocrinol 2003;31:349-57.
34. Giguere V. To ERR in the estrogen pathway. Trends Endocrinol Metab 2002;13:220-5.
35. Sun P, Sehouli J, Denkert C, Mustea A, Könsgen D, Koch I, Wei L, Lichtenegger W. Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med 2005;83:457-67.
36. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 2002;62:6510-18.